title: Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis.
authors.affiliation: Department of Autoimmunity, Transplantation and Inflammation, Novartis Institutes for BioMedical Research, Novartis Campus Forum 1, WSJ-386, CH-4056 Basel, Switzerland. volker.brinkmann@novartis.com
authors.forename: Volker
authors.initials: V
authors.lastname: Brinkmann
authors.forename: Andreas
authors.initials: A
authors.lastname: Billich
authors.forename: Thomas
authors.initials: T
authors.lastname: Baumruker
authors.forename: Peter
authors.initials: P
authors.lastname: Heining
authors.forename: Robert
authors.initials: R
authors.lastname: Schmouder
authors.forename: Gordon
authors.initials: G
authors.lastname: Francis
authors.forename: Shreeram
authors.initials: S
authors.lastname: Aradhye
authors.forename: Pascale
authors.initials: P
authors.lastname: Burtin
mesh_terms: D000284:Administration, Oral; D000818:Animals; D055808:Drug Discovery / Q000639:trends*; D000068876:Fingolimod Hydrochloride; D006801:Humans; D018836:Inflammation Mediators / Q000008:administration & dosage; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000473:pathology; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy / Q000473:pathology; D011409:Propylene Glycols / Q000008:administration & dosage*; D012106:Research / Q000639:trends*; D013110:Sphingosine / Q000008:administration & dosage / Q000031:analogs & derivatives*
chemical_list: D018836:Inflammation Mediators; D011409:Propylene Glycols; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine